“Latest Stem Cells News”

The first successful stem cell therapy for traumatic brain injury in the country was conducted by doctors at BGS Global
Hospitals.

Through this therapy, bone marrow was transplanted directly into the brain. N K Venkataramana, chief neurosurgeon of BGS Hospitals, confirmed that this is the first such attempt in India and second in the world. “China made the first attempt.”

The therapy was done on Madhumalika, 27, who was admitted to BGS Global Hospitals following a road accident on December 14 last year. She suffered from `diffuse axonal brain injury’ — a severe form of brain injury where the patient remains unconscious for a variable period. The patient needs to be assisted in his or her daily activities. In her case, she remained in a coma for more than three months.

Her mother had to resign from work and her father opted for the voluntary retirement scheme to look after their only daughter. “We had no hope of getting her back after the fatal injury. Also, we were unsure of the effects of the therapy on her. But we had to take a chance,” her father said.

In the surgery done in March, four million stem cells per body weight, which were prepared at Stempeutics Research Pvt Ltd, were injected directly into her brain.

After a month of the transplant, she showed considerable improvement. She became conscious, started talking and could move her limbs. She was also able to recognize family members and friends. But the prolonged stay in bed resulted in stiffness of the joints, for which she is undergoing physiotherapy.

Venkataramana said the belief that brain injuries aren’t curable has been proved wrong. “The need to help accident victims led us to work on stem cell therapy,” he added.

“Since 2004, there has been a pressing need to help the rising number of people who were disabled following road accidents. Stem cell therapy was one of the means to face the situation,” he explained.

“We’re planning to carry out a pilot study in treating head injuries with stem cells.”

from The Times of India

Incoming search terms:

Dr. Feng Lin, Director of Research at Bio-Matrix Scientific Group Inc. (OTCBulletinBoard: BMSN) and Entest BioMedical Inc., today stated that he believes that an effective new therapy for “traumatic brain injury” (TBI) using autologous “adipose-derived” stem cells represents a potential cure for TBI. According to Dr. Lin, both Bio-Matrix and Entest BioMedical are now studying the “therapeutic effect of fat stem cells on traumatic brain injury-associated brain ischemia and inflammation and replacement of damaged neurons with neuron cells differentiated from fat cells.” Bio-Matrix Scientific Group Inc. and Entest BioMedical Inc. recently submitted a research summary proposal to the U.S. Army with a goal of funding traumatic brain injury treatment research. BMSN is a San Diego-based biotechnology research and development company. Entest BioMedical Inc. is a wholly-owned subsidiary of BMSN. Entest is focusing on stem cell research applications, as well as testing procedures for diabetes.

“Currently there is no effective therapeutic approach to reverse the initial brain damage caused by trauma,” stated Dr. Lin. “Brain cells or neurons have limited ability for self-repair and spontaneous axonal regeneration. Extensive studies have been focusing on novel therapeutic strategies for traumatic brain injury. In my opinion, adipose-derived stem cells could possess the capacity for self-renewal and differentiation into diverse cell types such as neural cells. We could be looking at an exciting and potential cure for traumatic brain injury patients.”

Traumatic brain injury (TBI) occurs when an external force injures the brain. TBI is a major cause of disability and death worldwide, but especially in young people. Causes include vehicle accidents, falls, violence, as well as explosive blasts in battle fields. In the U.S., approximately 1.5 million new TBI cases occur each year, adding to the almost 6.5 million cases that are permanently affected by the irreversible physical, cognitive, and psychological defects associated with TBI. The total annual economic impact of TBI is approximately $60 billion.

Incoming search terms: